NCT05243342CompletedPhase 1
A Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Participants With Relapsed/Refractory Multiple Myeloma
A Phase Ib, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination With Daratumumab in Patients With Relapsed/Refractory Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 17 Feb 2025
Brief summary (registry, in English)
This study will evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with a multiple myeloma (MM)-targeting monoclonal antibody capable of inducing antibody-dependent cellular toxicity (ADCC) in participants with relapsed or refractory (R/R) MM who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- First submitted
- 1 Feb 2022
- Start date
- 28 Apr 2022
- Primary completion date
- 10 Jul 2024
- Lead sponsor
- Genentech, Inc.
- Diseases
- Multiple myeloma
- NCT number
- NCT05243342
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 18
- From 28 Apr 2022 to the primary completion date, 10 Jul 2024
- 7 sites in 4 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study design.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Any anti-cancer therapy within 3 weeks prior to initiation of study treatment, with exceptions defined by the protocol
- Prior allogeneic stem cell or solid organ transplantation
- Autologous stem cell transplantation within 100 days prior to initiation of study treatment
- Known active infection requiring IV anti-microbial therapy within 14 days prior to first study drug administration
Other illness
- Significant cardiovascular disease
- Known clinically significant liver disease
- Active or history of autoimmune disease or immune deficiency
Other
- Primary or secondary plasma cell leukemia
- Current CNS involvement by MM
- Other protocol defined inclusion/exclusion criteria may apply
Who the study is looking for
- Life expectancy of at least 12 weeks
- Measurable disease, as defined by the protocol
- Participants must have received a minimum of 3 prior lines of therapy, including at least one PI, one IMiD, and an anti-CD38 monoclonal antibody
- Best response of stable disease or better with at least one prior anti-CD38 monoclonal antibody containing line of treatment
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Royal Adelaide Hospital Coordinator of this site? Confirm its status | Adelaide | Australia | Unknown status |
| Alfred Hospital Coordinator of this site? Confirm its status | Melbourne | Australia | Unknown status |
| Odense Universitetshospital Coordinator of this site? Confirm its status | Odense C | Denmark | Unknown status |
| Sygehus Lillebælt - Vejle Coordinator of this site? Confirm its status | Vejle | Denmark | Unknown status |
| Hospital Universitario Germans Trias i Pujol Coordinator of this site? Confirm its status | Badalona | Spain | Unknown status |
| Hospital Universitari Vall d'Hebron Coordinator of this site? Confirm its status | Barcelona | Spain | Unknown status |
| Oslo Universitetssykehus HF Coordinator of this site? Confirm its status | Oslo | Norway | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.